TEL AVIV and HAIFA, Israel, April 4, 2017 /PRNewswire/ --
The diagnostics company Emosis Ltd., BioRap Technologies and Rambam MedTech Ltd, the technology transfer companies of the Rappaport Institute at the Technion - Israel Institute of Technology and Rambam Healthcare Campus, have entered into an exclusive license agreement to develop and commercialize hypercoagulation kit.
Prof. Benjamin Brenner and Prof. Anat Aharon from the Rappaport Institute and Rambam Healthcare Campus developed a proprietary technology enabling measurement of microparticles based biomarker for identifying and monitoring high risk patients who should be treated for coagulation complications.
Emosis will use its know-how and IP to develop the biomarker as a commercial kit while BioRap Technologies and Rambam MedTech will perform some of the supporting research.
"We are excited with the opportunity to collaborate with Emosis and jointly develop novel hypercoagulation kit based on these novel biomarkers," commented Dr. Orit Shaked, Biorap Technologies CEO.
"The licensed technology perfectly matches Emosis ambition to develop cell-based hemostasis assays, and it complements very well our existing technology platform. This is especially of importance to assess blood clotting risk in cancer," added Dr. Frédéric Allemand, Board Member of Emosis Ltd.
"We are proud to partner with such prominent Israeli research institutions. This collaboration, on the intensively studied topic of microparticles, is a founding step for Emosis Ltd. and the development of our local R&D capabilities," commented Aurore André, CEO of Emosis Ltd.
About Emosis Ltd.
Emosis Ltd is the affiliate of Emosis SAS, a French MedTech founded by Prof. Aaron Tomer and Dr. Frederic Allemand, to address largely unmet testing needs of patients presenting conditions associated with hemostasis and thrombosis disorders. Emosis uniquely applies, in a user-friendly way, the power of flow cytometry technology within the emerging paradigm of cell-based hemostasis, with a particular focus on microparticles for Emosis Ltd., to enlighten decision of the physicians managing those patients. Visit http://www.emosis-diagnostics.com
About Rambam MedTech
Rambam MedTech is the technology transfer company for Rambam Healthcare Campus, and serves as the industrial liaison to bring medical innovations to market. Visit http://www.rambammedtech.com
About BioRap Technologies
BioRap is the Rappaport Institute's technology transfer company. The company provides the legal framework for the inventions and innovations of RI researchers, protecting discoveries and innovations with patents, and working with industry to bring scientific discovery to the market. Visit http://www.bio-rap.com
Contact: Aurore André, CEO Emosis Ltd, +972-50-422-62-67, email@example.com
SOURCE Emosis Ltd, BioRap Technologies Ltd and Rambam MedTech Ltd